Oncology Biomarker Diagnostics

Linking molecular status to breakthroughs in cancer treatment

Publications

Development and Validation of a NOTCH Custom NGS Assay for Identifying NOTCH1 Mutations in Chronic Lymphocytic Leukemia and Other Lymphoid Malignancies

EHA 19th Congress 2014: Abstract P861

Quantitative Assessment of Circulating BRAF DNA on Stage IV Melanoma Patients Undergoing BRAF Inhibitor Treatment

AACR 2014 Annual Meeting: Abstract 2847

Phasing Analysis of TKI Resistance Mutations in the BCR-ABL1 Kinase Domain and Neighboring Domains Using Next-Generation Sequencing
Blood (ASH Annual Meeting Abstracts) 2013(21): Abstract 3817

 

Development and Validation of Highly Sensitive MRDx BCR-ABL Test for Monitoring Deep Molecular Response in Patients with Chronic Myeloid Leukemia
Blood (ASH Annual Meeting Abstracts) 2013(21): Abstract 2617

 

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)
Blood (ASH Annual Meeting Abstracts) 2013(21): Abstract 652

 

 

Liquid Biopsy: Analytical Validation of a Plasma-Based BRAF V600 AS-PCR Assay
Society for Melanoma Research 2013 Congress, Pigment Cell & Melanoma Research, 26: 932–1019 

 

 

FFPE DNA Quality:  Impact on Downstream Performance in Molecular Diagnostic Assays
Journal of Molecular Diagnostics 2013, Vol. 15, No. 6, Abstract TT31

 

Obtaining Maximal Information from Limited FFPE Tissue Specimens: Development and Validation of a 4-Gene Custom NGS Panel for a GIST Clinical Trial
ASCO-EORTC-NCI Markers in Cancer 2013 Poster; EJC 49, Suppl 4, MC13-0069 

 

Mutation detection in FFPE and plasma circulating DNA with a focused ALK-EGFR-KRAS Next-Generation Sequencing panel
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013 Poster

 

 

 

Evaluation of HGF and MET protein expression in NSCLC tumor specimens from patients previously treated with targeted or chemotherapies
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013 Poster

 

 

 

Clinical assessment of MUC1 protein expression in FFPE tissue: Development and validation of an immunohistochemistry assay as a predictive assay for response to MUC1 vaccines
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2013 Poster

 

 

Analysis of plasma-based BRAF and NRAS mutation detection in patients with stage III and IV melanoma
ASCO Annual Meeting 2013 Poster

Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
Mol Cancer Ther 2013 May;12(5):632-42. doi: 10.1158/1535-7163.MCT-12-0999. Epub 2013 Feb 26.

Validation of Illumina TruSeq® Amplicon Cancer Panel with Concordance Testing Using Ion AmpliSeq Cancer Panel and Other Methods
AACR Annual Meeting Poster 2013 Abstract 3229

AACR 2013 NGS Poster

Complementary Analysis of LKB1/STK11 Mutation and Protein Expression Statususing Next-Generation Sequencing, Sanger Sequencing and Immunohistochemistry
AACR Annual Meeting Poster 2013: Abstract 3509

LKB1 AACR 2013 Poster

Highly Sensitive Detection of EGFR T790M on Ion Torrent PGM
AACR Annual Meeting Poster 2013: Abstract 3490

EGFR T790M AACR 2013 Poster

Absolute Quantification of EGFR Activation and Resistance Mutations by Droplet Digital PCR in Circulating Nucleic Acids
AACR Annual Meeting Poster 2013: Abstract 3491

EGFR ddPCR AACR Poster

Clinical Assessment of PTEN mutation in FFPE Tissue: Comparison of Sanger Sequencing, Immunohistochemistry and Chromogenic In Situ Hybridization Methods
AACR Annual Meeting Poster 2013: Abstract 39

AACR 2013 PTEN Poster

Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance
Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 2549

NGS BCR-ABL Kinase Domain Poster

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial
Blood (ASH Annual Meeting Abstracts) 2012 120(21): Abstract 3763

 

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial
Blood (ASH Annual Meeting Abstracts) 2012 120(21): Abstract 915

 

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial
Blood (ASH Annual Meeting Abstracts) 2012 120(21): Abstract 3749

 

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Blood (ASH Annual Meeting Abstracts) 2012 120(21): Abstract 163

 

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
Blood (ASH Annual Meeting Abstracts) 2012 120(21): Abstract 3747

 

Liquid Biopsy: the Application of Allele-Specific PCR (AS-PCR) and Mutation-Directed SNaPshot Assay to Detect BRAF and NRAS Mutant DNA in Peripheral Blood from Metastatic Melanoma Patients
Journal of Molecular Diagnostics 2012, Vol. 14, No. 6; Abstract ST57

Liquid Biopsy AS-PCR Poster

Analytical Validation of Ion Amplicon Seq Cancer Panel 2.0
Journal of Molecular Diagnostics 2012, Vol. 14, No. 6; Abstract TT43

Analytical Validation of Ion Amplicon Seq Cancer Panel  Poster

Non-Invasive Absolute Quantification of EGFR Activating Mutation L858R and Gatekeeper Mutation T790M in NSCLC Plasma Samples Using Droplet Digital PCR
European Journal of Cancer 2012, Vol. 48, Supplement 6; Pages 139-140

Non-Invasive Absolute Quant. EGFR Poster

Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation
Blood (ASH Annual Meeting Abstracts) 2011 118(21): Abstract 109

 

Beyond V600E: Comprehensive Genotyping of BRAF Codon 600
Journal of Molecular Diagnostics 2011, Vol. 13, No. 6; Abstract ST17

Beyond V600E:  Comp. Genotyping of BRAF Codon 600

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Blood 2011 118: 5250-5254

BCR-ABL35INS insertion/truncation poster

An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients
Blood (ASH Annual Meeting Abstracts) 2007 110(11): Abstract 2939

 

Validation of Paxgene Tubes for BCR-ABL Quantitation at MMR Value Using 105 Paired Samples
Journal of Molecular Diagnostics 2007, Vol 9, No. 5: Abstract H23

 

A novel, high-throughput assay for detection of ABL T315I mutations
First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Sep 12-15, 2006; Abstract B68

 

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes